Business
vTv Therapeutics to Participate in Upcoming May Investor Conferences
HIGH POINT, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in May: H.C. Wainwright 4th Annual BioConnect Investor ConferenceFormat: Fireside Chat & one-on-one investor
About this update from Vtv Therapeutics Inc.
[{"type":"image","alt":"vTv Therapeutics Inc.","displaySize":"","headline":null,"caption":"vTv Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":156,"url":"https://media.zenfs.com/en/globenewswire.com/6b6b541287fc9ae12df42673a7e33331"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CMzU8dcpBB8s5raYZpw8kA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxOA--/https://media.zenfs.com/en/globenewswire.com/6b6b541287fc9ae12df42673a7e33331","width":300,"height":156},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/CMzU8dcpBB8s5raYZpw8kA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxOA--/https://media.zenfs.com/en/globenewswire.com/6b6b541287fc9ae12df42673a7e33331","width":300,"height":156}},"lazy":false},{"type":"text","content":"HIGH POINT, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in May:","length":404,"tagName":"p"},{"type":"text","content":"H.C. Wainwright 4th Annual BioConnect Investor ConferenceFormat: Fireside Chat & one-on-one investor meetingsDate: Tuesday, May 19, 2026Time: 12:30 PM ETLocation: New York, NYWebcast Link","length":201,"tagName":"p"},{"type":"text","content":"Alliance Global Partners Healthcare Company ShowcaseFormat: Fireside ChatDate: Wednesday, May 20, 2026Time: 4:20 PM ETLocation: Virtual EventEvent Webcast Link","length":169,"tagName":"p"},{"type":"text","content":"Live webcasts of the fireside chats will be available on the Media & Events section of the Company’s website at vtvtherapeutics.com. Replays of the webcasts will be available following the event.","length":199,"tagName":"p"},{"type":"text","content":"About vTv TherapeuticsvTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a U.S. Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes...